Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, single-sequence DDI study designed to examine the effects of dupilumab on the pharmacokinetics of selected cytochrome P450 substrates in adult patients with moderate to severe AD.

The study consists of a screening period (day -35 to -2), study period 1 (day -1 to 7), study period 2 (day 8 to 50), and a follow-up period (day 51 to 135 \[end of study\]).

Following completion of study period 2 (Day 50), patients will be given the option to enroll into the Open-Label Extension (OLE) study R668-AD-1225. Patients who decline will be followed for the next 12 weeks (Day 135).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277769

Dermatitis, Atopic

COMPLETED PHASE3

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986

Atopic Dermatitis

COMPLETED PHASE3

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

NCT01385657

Atopic Dermatitis

COMPLETED PHASE1

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

NCT01949311

Atopic Dermatitis

COMPLETED PHASE3

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT01639040

Atopic Dermatitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Period 1

Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)

Group Type EXPERIMENTAL

Midazolam

Intervention Type DRUG

Cytochrome P450 substrate

Omeprazole

Intervention Type DRUG

Cytochrome P450 substrate

Warfarin

Intervention Type DRUG

Cytochrome P450 substrate

Caffeine

Intervention Type DRUG

Cytochrome P450 substrate

Metoprolol

Intervention Type DRUG

Cytochrome P450 substrate

Period 2

Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).

Group Type EXPERIMENTAL

Dupilumab

Intervention Type DRUG

Midazolam

Intervention Type DRUG

Cytochrome P450 substrate

Omeprazole

Intervention Type DRUG

Cytochrome P450 substrate

Warfarin

Intervention Type DRUG

Cytochrome P450 substrate

Caffeine

Intervention Type DRUG

Cytochrome P450 substrate

Metoprolol

Intervention Type DRUG

Cytochrome P450 substrate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dupilumab

Intervention Type DRUG

Midazolam

Cytochrome P450 substrate

Intervention Type DRUG

Omeprazole

Cytochrome P450 substrate

Intervention Type DRUG

Warfarin

Cytochrome P450 substrate

Intervention Type DRUG

Caffeine

Cytochrome P450 substrate

Intervention Type DRUG

Metoprolol

Cytochrome P450 substrate

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

REGN668/SAR231893

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patient, aged 18 years or older
2. Diagnosis of Chronic AD, defined as diagnosis of AD for at least 3 years before the screening visit
3. Eczema Area Severity Index (EASI) score ≥16 at the screening and baseline visits
4. Investigator's Global Assessment (IGA) score ≥3 (on the 0 to 4 IGA scale) at the screening and baseline visits
5. ≥10% Body Surface Area (BSA) of AD involvement at the screening and baseline visits
6. Patients with documented recent history (within 6 months before the screening visit) of inadequate response to outpatient treatment with topical medications, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks)
7. Provide signed informed consent

Exclusion Criteria

1. Prior participation in a dupilumab clinical trial
2. The use of any of the following treatments within 4 weeks before the baseline visit:

* Systemic corticosteroids
* Immunosuppressive/immunomodulating drugs
* Phototherapy for AD
3. Administration, within 14 days before baseline or within a period of 5 times the elimination half-life of the medication before baseline, whichever is longer, of any medication that is a known inducer or inhibitor of either one or more of the following CYP enzymes: CYP3A, CYP2C19, CYP2C9, CYD2D6, and CYP1A2. Patients who are on any of these medications at the time of screening and cannot be safely taken off these medications will be excluded from the study.
4. Any contraindication to one or more of the following drugs, according to the applicable labeling:

* Midazolam
* Omeprazole
* Warfarin
* Caffeine
* Metoprolol
5. Consumption of any 1 or more of the following food items and/ or beverages within 1 week prior to baseline:

* Grapefruit or grapefruit juice, apple or apple juice, orange or orange juice, lemons or lemon juice, limes or lime juice
* Vegetables from the mustard green family (eg, broccoli)
* Charbroiled meats
* Caffeinated beverages, foods or drugs containing caffeine Patients who are not willing to abstain from the consumption of these food items and/or beverages for certain periods during the study will also be excluded
6. History of excessive consumption of beverages containing caffeine (more than 4 cups or glasses per day). Patients who are not willing to abstain from the consumption of caffeine during certain periods of the study will also be excluded
7. History or presence of alcohol or drug abuse within last 2 years
8. History of smoking within last 2 years
9. Poor metabolizers for CYP2C9, CYP2C19, or CYP2D6 based on genotyping
10. Presence of any one or more of the following lab abnormalities at screening:

* Platelet count ≤100 x 10\^3/µL
* Neutrophils ≤1 x 10\^3/µL
* Creatinine phosphokinase (CPK) \>10 x upper limit of normal (ULN)
* International normalized ratio (INR) ≥2
11. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit, or superficial skin infections within 1 week before the screening visit
12. Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the investigator
13. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening
14. Positive with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (Hep C Ab) at the screening visit. NOTE: Patients who are HBsAg negative and HBsAb positive are considered immune after a natural infection has cleared or they have been vaccinated against hepatitis B. Therefore, they are acceptable for the study.
15. History of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix, and completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin
16. History of clinical endoparasitosis (ie, helminth infection) within 12 months before the baseline visit, or high risk of helminth infection, such as residence within or recent travel (within 12 months before the baseline visit) to areas endemic for endoparasitoses, where the circumstances are consistent with parasite exposure (eg, extended stay, rural or slum areas, lack of running water, consumption of uncooked, undercooked, or otherwise potentially contaminated food, close contact with carriers and vectors, etc), unless subsequent medical assessments (eg, stool exam, blood tests, etc) have ruled out the possibility of parasite infection/infestation
17. Female patients who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
18. Women who are using any form of hormonal contraceptives (eg, oral, injectables, implants, patches, rings, hormone-impregnated intrauterine devices \[IUDs\]) for birth control
19. Women unwilling to use adequate birth control, if of reproductive potential and sexually active.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No